Silvina Stella Maris Villanueva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Silvina Stella Maris Villanueva has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Aldo Domingo Mottino
Instituto de Fisiología Experimental (IFISE-CONICET)-Facultad de Ciencias Bioquímicas y Farmacéuticas-Universidad Nacional de Rosario, Rosario, Argentina
7 shared publications - Guillermo Nicolás Tocchetti
Instituto de Fisiología Experimental (IFISE-CONICET)-Facultad de Ciencias Bioquímicas y Farmacéuticas-Universidad Nacional de Rosario, Rosario, Santa Fe, Argentina
7 shared publications - Juan Pablo Rigalli
Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
7 shared publications Fabiana García
Laboratorio de Fisiología Metabólica-CONICET-Facultad de Ciencias Médicas-Universidad Nacional de Rosario, Rosario, Argentina
5 shared publicationsFelipe Zecchinati
Instituto de Fisiología Experimental (IFISE)-CONICET-Facultad de Ciencias Bioquímicas y Farmacéuticas-Universidad Nacional de Rosario, Rosario, Argentina
5 shared publicationsMaite Rocío Arana
Instituto de Fisiología Experimental (IFISE)-CONICET-Facultad de Ciencias Bioquímicas y Farmacéuticas-Universidad Nacional de Rosario, Rosario, Argentina
5 shared publications
Latest Publications
- Open Access
- 6 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (12) , 1575
Inulin Reverses Intestinal Mrp2 Downregulation in a Diet-Induced Obesity Mouse Model: Role of Intestinal Microbiota as a Pivotal Modulator
Background: The intestinal microbiota (IM) modulates host physiology, and its alteration (dysbiosis) is associated with numerous diseases, including obesity. This condition influences the pharmacokinetics of drugs prescribed for related comorbidities, although the underlying mechanisms remain poorly understood. Mrp2, an essential ABC transporter of the intestinal biochemical barrier, regulates the absorption of dietary toxins and orally administered drugs, modulating their bioavailability. However, its regulation in the obesity context is poorly characterized, and the role of IM alteration in this process remains unknown. Objective: To evaluate the role of the IM as a key factor, along with downstream candidate mediators, in the regulation of Mrp2 under obesity conditions. Methods: Male C57BL/6 mice were fed either a control diet or High-Fat Diet (HFD) for 8 weeks, followed by 2 weeks with or without 5% inulin, a well-known prebiotic, supplementation. Metabolic and biochemical parameters were evaluated. Intestinal barrier integrity, inflammatory cytokines, oxidative stress (OS) markers, and plasma endotoxin levels were assessed. Mrp2 expression was analyzed at mRNA and protein levels, and transporter activity was determined using the everted intestinal sac model. Fecal microbiota composition was characterized by 16S rRNA sequencing. Results: HFD feeding induced obesity, insulin resistance, hyperglycemia, dyslipidemia, intestinal dysbiosis, elevated endotoxemia, barrier dysfunction, inflammation, and OS. These alterations were associated with a marked downregulation of Mrp2 expression and activity. Inulin supplementation restored IM composition, improved metabolic and intestinal parameters, and reduced inflammation and OS. These positive changes correlated with normalization of Mrp2. Conclusions: Our findings provide the first evidence that intestinal dysbiosis, inflammation, and OS act as a central regulatory axis of intestinal Mrp2 in obesity, with the IM functioning as a key modulator.
- 6 December 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (12) , 1575
Open AccessInulin Reverses Intestinal Mrp2 Downregulation in a Diet-Induced Obesity Mouse Model: Role of Intestinal Microbiota as a Pivotal Modulator
Background: The intestinal microbiota (IM) modulates host physiology, and its alteration (dysbiosis) is associated with numerous diseases, including obesity. This condition influences the pharmacokinetics of drugs prescribed for related comorbidities, although the underlying mechanisms remain poorly understood. Mrp2, an essential ABC transporter of the intestinal biochemical barrier, regulates the absorption of dietary toxins and orally administered drugs, modulating their bioavailability. However, its regulation in the obesity context is poorly characterized, and the role of IM alteration in this process remains unknown. Objective: To evaluate the role of the IM as a key factor, along with downstream candidate mediators, in the regulation of Mrp2 under obesity conditions. Methods: Male C57BL/6 mice were fed either a control diet or High-Fat Diet (HFD) for 8 weeks, followed by 2 weeks with or without 5% inulin, a well-known prebiotic, supplementation. Metabolic and biochemical parameters were evaluated. Intestinal barrier integrity, inflammatory cytokines, oxidative stress (OS) markers, and plasma endotoxin levels were assessed. Mrp2 expression was analyzed at mRNA and protein levels, and transporter activity was determined using the everted intestinal sac model. Fecal microbiota composition was characterized by 16S rRNA sequencing. Results: HFD feeding induced obesity, insulin resistance, hyperglycemia, dyslipidemia, intestinal dysbiosis, elevated endotoxemia, barrier dysfunction, inflammation, and OS. These alterations were associated with a marked downregulation of Mrp2 expression and activity. Inulin supplementation restored IM composition, improved metabolic and intestinal parameters, and reduced inflammation and OS. These positive changes correlated with normalization of Mrp2. Conclusions: Our findings provide the first evidence that intestinal dysbiosis, inflammation, and OS act as a central regulatory axis of intestinal Mrp2 in obesity, with the IM functioning as a key modulator.
- Open Access
- 16 October 2025
- Published by MDPI AG in Preprints.org
Inulin Reverses Intestinal Mrp2 Downregulation in a Diet-Induced Obesity Mouse Model: Role of Intestinal Microbiota as a Pivotal Modulator
Background: The intestinal microbiota (IM) modulates host physiology, and its alteration (dysbiosis) is associated with several diseases, including obesity. This condition influences the pharmacokinetics of drugs prescribed for related comorbidities, although the underlying mechanisms remain poorly understood. Mrp2, an essential ABC transporter of the intestinal biochemical barrier, regulates the absorption of dietary toxins and orally administered drugs, thereby modulating their bioavailability. However, its regulation in the obesity context is poorly characterized, and the role of IM alteration in this process remains unknown. Objective: To evaluate the role of the IM as a key factor, along with downstream candidate mediators, in the regulation of Mrp2 under obesity conditions. Methods: Male C57BL/6 mice were fed either a control diet or High-Fat Diet (HFD) for 8 weeks, followed by 2 weeks with or without 5% inulin supplementation. Metabolic and biochemical parameters were evaluated. Intestinal barrier integrity, inflammatory cytokines, oxidative stress (OS) markers, and plasma endotoxin levels were assessed. Mrp2 expression was analyzed at mRNA and protein levels, and transporter activity was determined using the everted intestinal sac model. Fecal microbiota composition was characterized by 16S rRNA sequencing. Results: HFD feeding induced obesity, insulin resistance, hyperglycemia, dyslipidemia, intestinal dysbiosis, elevated endotoxemia, barrier dysfunction, inflammation, and OS. These alterations were associated with marked downregulation of Mrp2 expression and activity. Inulin supplementation restored IM composition, improved metabolic and intestinal parameters, and reduced inflammation and OS. These positive changes correlated with normalization of Mrp2. Conclusion: Our findings provide the first evidence that intestinal dysbiosis, inflammation, and OS act as a central regulatory axis of intestinal Mrp2 in obesity, with the IM functioning as a key modulator.
- 16 October 2025
- Published by MDPI AG in Preprints.org
Open AccessInulin Reverses Intestinal Mrp2 Downregulation in a Diet-Induced Obesity Mouse Model: Role of Intestinal Microbiota as a Pivotal Modulator
Background: The intestinal microbiota (IM) modulates host physiology, and its alteration (dysbiosis) is associated with several diseases, including obesity. This condition influences the pharmacokinetics of drugs prescribed for related comorbidities, although the underlying mechanisms remain poorly understood. Mrp2, an essential ABC transporter of the intestinal biochemical barrier, regulates the absorption of dietary toxins and orally administered drugs, thereby modulating their bioavailability. However, its regulation in the obesity context is poorly characterized, and the role of IM alteration in this process remains unknown. Objective: To evaluate the role of the IM as a key factor, along with downstream candidate mediators, in the regulation of Mrp2 under obesity conditions. Methods: Male C57BL/6 mice were fed either a control diet or High-Fat Diet (HFD) for 8 weeks, followed by 2 weeks with or without 5% inulin supplementation. Metabolic and biochemical parameters were evaluated. Intestinal barrier integrity, inflammatory cytokines, oxidative stress (OS) markers, and plasma endotoxin levels were assessed. Mrp2 expression was analyzed at mRNA and protein levels, and transporter activity was determined using the everted intestinal sac model. Fecal microbiota composition was characterized by 16S rRNA sequencing. Results: HFD feeding induced obesity, insulin resistance, hyperglycemia, dyslipidemia, intestinal dysbiosis, elevated endotoxemia, barrier dysfunction, inflammation, and OS. These alterations were associated with marked downregulation of Mrp2 expression and activity. Inulin supplementation restored IM composition, improved metabolic and intestinal parameters, and reduced inflammation and OS. These positive changes correlated with normalization of Mrp2. Conclusion: Our findings provide the first evidence that intestinal dysbiosis, inflammation, and OS act as a central regulatory axis of intestinal Mrp2 in obesity, with the IM functioning as a key modulator.
- 1 August 2020
- Published by Elsevier in Toxicology
- Vol. 441, 152527
Role of interleukin 1 beta in the regulation of rat intestinal multidrug resistance-associated protein 2 under conditions of experimental endotoxemia
- 1 August 2020
- Published by Elsevier in Toxicology
- Vol. 441, 152527
Role of interleukin 1 beta in the regulation of rat intestinal multidrug resistance-associated protein 2 under conditions of experimental endotoxemia
- 18 March 2020
- Published by Springer Nature in Archives of Toxicology
- Vol. 94 (5) , 1625-1635
Regulation of hepatic P-gp expression and activity by genistein in rats
P-glycoprotein (P-gp) is an ABC transporter exhibiting high pharmacotoxicological relevance by extruding a wide range of cytotoxic compounds out of the cells. Previously, we demonstrated that the phytoestrogen genistein (GNT) modulates P-gp expression in hepatocellular carcinoma in vitro. Although several beneficial effects (e.g., antioxidant, antimutagenic, anticancer) have been attributed to GNT, the molecular mechanisms have not been totally elucidated. In the present work, we evaluated the effect of GNT on P-gp expression in rat liver, kidney and ileum. We found that GNT (5 mg/kg daily s.c. 3 days) increased hepatic P-gp expression and also Mdr1a (one of the genes encoding P-gp) mRNA levels. Renal and intestinal P-gp remained unchanged after GNT treatment. Hepatic P-gp activity measured with rhodamine-123 and digoxin, both well-known P-gp substrates, was also increased. In vitro experiments using hepatocyte primary cell culture demonstrated that inhibition of ER-α with ICI182/780 did not prevent Mdr1a mRNA up-regulation by GNT (10 µM). In contrast, Mdr1a induction was suppressed after pregnane X receptor (PXR) inhibition by sulforaphane and knockdown of this nuclear receptor. These findings were confirmed in vivo by using the PXR antagonist ketoconazole. In conclusion, we demonstrated the induction of hepatic P-gp expression and activity by GNT in vivo, with PXR being a likely mediator. This suggests that GNT, at concentrations observed in plasma of individuals consuming the phytoestrogen in the diet or through supplements, could affect the clearance of relevant P-gp substrates of therapeutic use as well as toxicity of environmental and food toxicants.
- 18 March 2020
- Published by Springer Nature in Archives of Toxicology
- Vol. 94 (5) , 1625-1635
Regulation of hepatic P-gp expression and activity by genistein in rats
P-glycoprotein (P-gp) is an ABC transporter exhibiting high pharmacotoxicological relevance by extruding a wide range of cytotoxic compounds out of the cells. Previously, we demonstrated that the phytoestrogen genistein (GNT) modulates P-gp expression in hepatocellular carcinoma in vitro. Although several beneficial effects (e.g., antioxidant, antimutagenic, anticancer) have been attributed to GNT, the molecular mechanisms have not been totally elucidated. In the present work, we evaluated the effect of GNT on P-gp expression in rat liver, kidney and ileum. We found that GNT (5 mg/kg daily s.c. 3 days) increased hepatic P-gp expression and also Mdr1a (one of the genes encoding P-gp) mRNA levels. Renal and intestinal P-gp remained unchanged after GNT treatment. Hepatic P-gp activity measured with rhodamine-123 and digoxin, both well-known P-gp substrates, was also increased. In vitro experiments using hepatocyte primary cell culture demonstrated that inhibition of ER-α with ICI182/780 did not prevent Mdr1a mRNA up-regulation by GNT (10 µM). In contrast, Mdr1a induction was suppressed after pregnane X receptor (PXR) inhibition by sulforaphane and knockdown of this nuclear receptor. These findings were confirmed in vivo by using the PXR antagonist ketoconazole. In conclusion, we demonstrated the induction of hepatic P-gp expression and activity by GNT in vivo, with PXR being a likely mediator. This suggests that GNT, at concentrations observed in plasma of individuals consuming the phytoestrogen in the diet or through supplements, could affect the clearance of relevant P-gp substrates of therapeutic use as well as toxicity of environmental and food toxicants.
- 1 February 2017
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 40, 178-186
Intestinal multidrug resistance-associated protein 2 is down-regulated in fructose-fed rats
- 1 February 2017
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 40, 178-186
Intestinal multidrug resistance-associated protein 2 is down-regulated in fructose-fed rats
- Open Access
- 26 October 2016
- Published by IntechOpen
Hepatic and Intestinal Multidrug Resistance-Associated Protein 2: Transcriptional and Post-transcriptional Regulation by Xenobiotics
Hepatic and Intestinal Multidrug Resistance-Associated Protein 2: Transcriptional and Post-transcriptional Regulation by Xenobiotics | InTechOpen, Published on: 2016-10-26. Authors: Maite R. Arana, Guillermo N. Tocchetti, Juan P. Rigalli, et
- 26 October 2016
- Published by IntechOpen
Open AccessHepatic and Intestinal Multidrug Resistance-Associated Protein 2: Transcriptional and Post-transcriptional Regulation by Xenobiotics
Hepatic and Intestinal Multidrug Resistance-Associated Protein 2: Transcriptional and Post-transcriptional Regulation by Xenobiotics | InTechOpen, Published on: 2016-10-26. Authors: Maite R. Arana, Guillermo N. Tocchetti, Juan P. Rigalli, et